November 2022 - Page 13 Of 32

3D Printing Medical Devices Market Size is projected to reach USD 9.79 Billion by 2031, growing at a CAGR of 16.1{bf0515afdcaddba073662ceb89fbb62b6b1bf123143c0e06b788e1946e8c353f}: Straits Research

The global 3D printing medical devices market size was valued at USD 2.55 billion in 2022. It is projected to reach USD 9.79 billion by 2031, growing at a CAGR of 16.1{bf0515afdcaddba073662ceb89fbb62b6b1bf123143c0e06b788e1946e8c353f} during the forecast period (2023-2031). North America is the most significant shareholder in the global 3D printing medical devices market.

New York, United States, Nov. 17, 2022 (GLOBE NEWSWIRE) — The process of producing three-dimensional solid objects from digital files or designs is referred to as additive manufacturing or 3D printing. Hollowing out or cutting a piece of metal or plastic makes it possible to produce intricate functional shapes. In 3D printing, an object is made by adding materials in successive layers until the desired shape is achieved. Throughout the healthcare lifecycle, medical printing devices provide users with a wide range of advantages. With the potential to be used as a widespread care pathway for complex injuries, 3D printing helps to improve treatment outcomes, procedural efficiency, and reintervention costs. During the forecast period, 2023–2031, medical and surgical facilities are anticipated to lead the demand for 3D-printed medical devices. The demand for 3D printed devices is also being boosted by the quick uptake of technological innovations such as portable, multi-material, colored 3D printers, and others in the medical sector. Additionally, 3D printing technology is revolutionizing the medical industry by enabling doctors to create individualized and patient-specific implants through novel applications in surgical implants and prosthetics.

Get a Free Sample Copy of This Report @ https://straitsresearch.com/report/3d-printing-medical-devices-market/request-sample

The surge in 3D Printing Investment Drives the Market

The amount of public-private funding for various 3D printing initiatives has significantly increased in recent years. The market for 3D-printed medical devices is expected to grow as a result of these research and funding initiatives, which are expected to hasten the development of 3D printing technologies and products. In September 2020, the U.S. company nTopology raised $40 million in funding for the development of the nTop software platform for additive manufacturing methods. At the University of Huddersfield, a new generation of electron-beam additive manufacturing (EBAM) printer was developed with the help of USD 2.6 million in funding from Innovate U.K. in March 2019. (U.K.).

Digital Manufacturing Innovation gives Opportunity for Exponential Growth

With the aim of improving clinical workflow, there has been a significant advancement in the digitization of dental and medical procedures over time. Traditional dental and surgical procedures are being replaced by digital versions. Using computer-controlled processes, direct digital manufacturing is the process of making a physical object directly from a digital design. As 3D printing technology advances, direct digital manufacturing is becoming more and more popular in comparison to traditional manufacturing processes. Because it reduces the time between design and production, does away with the need for tooling, and increases output, it has a unique set of advantages.

Report Scope

Report Metric	Details
Market Size	USD 9.79 billion by 2031
CAGR	16.1{bf0515afdcaddba073662ceb89fbb62b6b1bf123143c0e06b788e1946e8c353f} (2023-2031)
Historical Data	2020-2021
Base Year	2022
Forecast Period	2023-2031
Forecast Units	Value (USD Billion)
Report Coverage	Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
Segments Covered	Component, Technology, Application
Geographies Covered	North America, Europe, Asia-Pacific, LAME and Rest of the World
Key Companies Profiled/Vendors	3D Systems Corporations, Bio3D Technologies, Cyfuse Medical K.K., EnvisionTEC, Materialise NV, Organovo Holdings, Inc., Oxford Performance Materials, Inc., SLM Solutions Group AG, and Stratasys Ltd.
Key Market Opportunities	The Surge of Digital Manufacturing
Key Market Drivers	Rising Investment in 3D Printing Increasing Cases of Osteoarthritis

Buy Now Full Report @ https://straitsresearch.com/buy-now/3d-printing-medical-devices-market

Regional Analysis

North America is the most significant shareholder in the global 3D printing medical devices market and is expected to grow at a higher CAGR due to the region’s growing interest in 3D-printed medical devices and the rising demand for those devices. For instance, a U.S.-based service company called FORECAST 3D recently announced the purchase of 12 H.P. Jet Fusion 3D printers with the ability to provide full-run 3D manufacturing. In addition, the University of California (UCSF) and the Chinese 3D printer manufacturer INTAMSYS collaborated to launch the 3D printed orthopedics research initiative with technically advanced, reasonably priced orthopedic implants in June 2018.

Due to technological advancements, a strong and stable R&D environment, and innovation, Europe is expected to experience significant growth in the 3D printing medical devices market. Adidas and Carbon, a Silicon Valley 3D printing company, announced their collaboration in April 2017 to produce the “Futurecraft 4D” shoes, which feature 3D printed soles made using digital light synthesis technology. In July 2022, the 3D-printed bone graft manufactured by the medical device company Cerhum received approval for use in patients throughout Europe. MyBone is the first commercially available 3D-printed bone graft that has been authorized under the Medical Device Regulation 2017/745, according to reports. Additionally, it has obtained ISO 13485 certification. Thus, orthopedic and maxillofacial surgeons will now have access to the patient-specific bone graft across the continent.

During the anticipated period, the market for 3D-printed medical devices is likely to expand significantly in Asia Pacific. According to the E.U., as a result of government initiatives to promote the technological potential of orthopedics, the value chain for 3D-printed medical devices is gaining momentum. Additionally, nations like India and China are becoming more well-known due to factors like a rapidly aging population, a growing demand for cutting-edge healthcare, and others. In March 2022, Zoriox Innovation Labs will produce implants for facial reconstruction in India using 3D printing technology. In order to provide a 360-degree solution for facial reconstruction and related needs, a team of surgeons, dentists, mechanical engineers, biomedical engineers, software engineers, graphic designers, prosthetists, and anatomists collaborate at Zoriox Innovation Labs.

With several vendors expanding their operations and the implementation of favorable regulations in Latin America, the Middle East, and Africa, the LAMEA region is anticipated to experience moderate market growth. Using a 3D printed model of arteries to map out how to safely navigate the blood vessels, hospitals in Dubai have made it mandatory for doctors to use 3D printing to operate successfully on patients who have suffered a cerebral aneurysm in four veins.

Key Highlights

The global 3D printing medical devices market size was valued at USD 2.55 billion in 2022. It is projected to reach USD 9.79 billion by 2031, growing at a CAGR of 16.1{bf0515afdcaddba073662ceb89fbb62b6b1bf123143c0e06b788e1946e8c353f} during the forecast period (2023-2031).
Based on components, the global 3D printing medical devices market is bifurcated into Printers, Materials, and Software & Services. The software and services segment is the highest contributor to the market.
Based on technology, the global 3D printing medical devices market is bifurcated into electron beam melting, laser beam melting, selective laser sintering, photopolymerization, direct metal laser sintering, and others. The laser beam melting segment is expected to grow at a higher CAGR during the forecast period
Based on application, the global 3D printing medical devices market is bifurcated into orthopedic & cranial implants, dental restorations, surgical instruments, tissue fabrication, and custom prosthetics.
North America is the most significant shareholder in the global 3D printing medical devices market and is expected to grow at a higher CAGR during the forecast period.

The global 3D Printing Medical Devices market’s major key players are

Get a Free Sample Copy of This Report @ https://straitsresearch.com/report/3d-printing-medical-devices-market/request-sample

Global 3D Printing Medical Devices Market: Segmentation

By Component

Printers
Materials
Software & Services

By Technology

By Application

By Regions

North America
Europe
Asia-Pacific
LAMEA

Market News

In May 2022, Organovo Holdings Inc announced its 3D tissue model for Crohn’s disease.
In October 2022, Cyfuse Medical K.K got approval for listing on Tokyo Stock Exchange.

News Media

3D Printing an Emerging Technology for Dentistry and Dental Surgery

Have a Look at the Related Research Report

3D Bioprinting Market: Information by Technology (Magnetic Levitation) Application (Medical, Dental, Biosensors, Food, and Animal Products), and Region — Forecast till 2029

3D Printed Drug Market: Information By End User (Hospitals, Clinics, Research Laboratories) and Region— Forecast Till 2026

3D Optical Profiler Market: Information by Technology (Confocal Technology, White Light Interference), Industry Vertical, and Region — Forecast till 2026

3D Printing Materials Market: Information by Foam (Powder, Filament, Liquid), End-Use Industry (Automotive, Healthcare, Consumer Goods), Type, Technology, and Region — Forecast till 2029

About Straits Research Pvt. Ltd.

Straits Research is a market intelligence company providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision-makers. Straits Research Pvt. Ltd. provides actionable market research data, especially designed and presented for decision making and ROI.

Whether you are looking at business sectors in the next town or crosswise over continents, we understand the significance of being acquainted with the client’s purchase. We overcome our clients’ issues by recognizing and deciphering the target group and generating leads with utmost precision. We seek to collaborate with our clients to deliver a broad spectrum of results through a blend of market and business research approaches.

For more information on your target market, please contact us below:

Phone: +1 646 480 7505 (the U.S.)

+91 8087085354 (APAC)

+44 208 068 9665 (the U.K.)

Email: sales@straitsresearch.com

Follow Us: LinkedIn | Facebook | Instagram | Twitter

International Men’s Day 2022: Tips for men to reduce prostate cancer risk | Health

Prostate cancer occurs when the cells in the prostate gland which is found only in males start to grow out of control. Prostate gland is located just below the bladder and in front of the rectum and makes some of the fluid that is part of semen. Prostate cancer is the second most common cancer in men worldwide and unfortunately its incidence is increasing in India as it has moved from being the eighth most common cancer in males in 1990s to the third rank by 2015. It is the fifth leading cause of cancer-related deaths among men worldwide. (Also read: Prostate Cancer: Causes, symptoms, risk factors and treatment)

Can one prevent the prostate cancer? There are certain risk factors like age, race and genetics that cannot be modified while lifestyle factors can be modified to an extent.

“There is no proven strategy to prevent prostate cancer. Prostate cancer is primarily a disease of aging. As you get older, your chances of developing prostate cancer increase. Race and genetics also play a significant role. If your father, brother or multiple blood relatives had prostate cancer, you are more likely to get it, too. Worldwide African Americans have increased risk of having prostate cancer. These risk factors of age, race and genetics are non-modifiable risk factors. Preventing prostate cancer might be difficult if you have these risk factors, but screening early and often can help ensure that if you do get cancer, it’s diagnosed and treated as soon as possible,” says Dr Shrikanth Atluri, Consultant Uro-Oncologist and Robotic Surgeon within the division of Surgical Oncology (Cancer Surgery) at Sir HN Reliance Foundation Hospital, Mumbai.

LIFESTYLE FACTORS THAT INCREASE RISK OF PROSTATE CANCER

A wide variety of environmental or dietary factors may be associated with the risk of developing prostate cancer.

“Poor eating habits and diets that heavily rely on fats and animal proteins can cause DNA damage and lead to cancer. Even men who are already at greater risk due to age, race or genetics can reduce their chances of developing prostate cancer by adopting healthy diets and lifestyles. Improve your diet by reducing fat, charred meat, eating more fruits and vegetables, maintain healthy weight, regular exercise, stop smoking and drinking are the lifestyle changes to be adopted to which may help in reducing the risk of having a prostate cancer,” says Dr Atluri.

Dr. Preetam Kumar Jain – Senior Consultant Oncologist and Hematologist, Masina Hospital, says that although there is no definite method to reduce the risk of prostate cancer and certain risk factors are irreversible, there are studies that reversible risk factors when controlled can help in reducing the risk of prostate cancers. Dr Jain suggests some tips.

TIPS TO REDUCE RISK OF PROSTATE CANCER

– Healthy lifestyle: One should stay away from unhealthy food, eat nutritious food and sleep on time.

– Regular exercise: One should exercise 20 minutes a day and 5 days a week.

– Avoid Obesity: Staying physically active and eating healthy food can help. Weight problems should be addressed early.

– Maintain Body mass index

– Eating diets rich in antioxidants such as fruits and vegetables can help reduce risk of prostate cancer.

– Do not go overboard with dairy products and calcium content.

– Avoid diet containing red and processed meats.

– Some studies say that drugs that inhibit 5 alpha reductase inhibitors and aspirin may reduce the reduce the risk of prostate cancer and mortality. However, they are not FDA recommended as of now.

“It is also important to identify early symptoms of prostate related problem. Symptoms like frequent micturition, incomplete voiding of urine, nocturia, could be possible signs of prostate related problems. If you have a family history of prostate cancer, then the subsequent generation members are at a risk of prostate cancer, at least a decade earlier. Knowing this genetic susceptibility, you may have to remain alert as your age advances. New genetic studies are in the pipeline for better understanding of the prostate cancer. Mutation analysis like BRCA and HRR testing are now being recommended in patients with prostate cancer,” says Dr Jain.

Follow more stories on Facebook & Twitter

Does bread have cholesterol? White bread, rye and more

Bread does not generally contain cholesterol, but varieties that include animal products, such as milk and butter, do contain cholesterol. White bread and other types made from refined grains may raise a person’s cholesterol levels.

Bread is a staple food for many different cultures, and there are hundreds of unique types.

Some varieties of bread contain dietary cholesterol, while others may raise LDL, or “bad”, cholesterol levels in the blood. However, studies suggest dietary cholesterol has little effect on blood cholesterol levels.

This article further explains bread and cholesterol, the role of whole grains in managing cholesterol, and how people can follow a healthy diet to lower the risk of heart disease.

The cholesterol content of bread depends on certain factors.

There are two types of cholesterol: one in the blood and another in food, known as dietary cholesterol.

Most bread is made with flour, water, and yeast and contains no cholesterol. But some types are made using animal products with high levels of saturated fats, which often contain cholesterol.

Additionally, bread made from white or refined grains can raise LDL cholesterol levels. We explore this in further detail below.

Saturated and trans fats

Some varieties of bread contain animal products such as milk, butter, or eggs, which contain saturated fat.

According to the Centers for Disease Control and Prevention (CDC), foods higher in saturated fats usually contain lots of cholesterol.

However, dietary cholesterol has little effect on a person’s blood cholesterol. Saturated and trans fats in foods have a greater effect on increasing a person’s cholesterol levels.

Learn more about types of fat.

Below is a table of the approximate cholesterol and saturated fat content of various types of bread.

White bread

White bread contains refined bread flour — a process that removes the bran and germ to give the flour a finer texture.

However, the process also removes essential nutrients such as:

Therefore, manufacturers add in vitamins by “enriching” refined flour but do not replace the fiber.

This lack of fiber means that white bread is less likely to make a person feel full and more likely to overeat. Refined grains, also known as refined carbohydrates, are also digested more quickly by the body, which can raise blood sugar levels.

A person with high blood sugar levels is more likely to have higher LDL cholesterol levels and lower HDL, or good, cholesterol.

Learn more about the difference between LDL and HDL cholesterol.

Types of white bread include:

ciabatta
white pitta bread
white baguettes
focaccia
white sourdough
white wheat tortillas
flatbread
white sandwich loaf

Whole grain bread contains all the nutrients and fiber from grains, making it a good dietary fiber source.

The CDC states that fiber prevents the body from taking in some fat and cholesterol. This can lower triglyceride levels — another type of fat in the blood — and cholesterol levels and reduce the risk of heart disease.

A 2019 study also found that replacing white bread, which has a high glycemic index (GI) with wholemeal bread, which has a low GI, for breakfast slowed the body’s glycemic response. Research links higher blood sugar levels with high levels of LDL cholesterol.

Types of whole grain bread include those made with the following:

whole wheat
whole barley
brown rice
whole grain oats
rolled oats
sprouted grains
whole rye
multi whole grains

Learn more about what makes whole grains so healthy.

Here are some answers to common questions about bread and cholesterol.

Does rye bread have cholesterol?

Rye bread does not have dietary cholesterol, as it does not contain butter or other animal products.

Does gluten-free bread have cholesterol?

Gluten-free bread made with animal products, such as milk, butter, or eggs, may contain some cholesterol.

Learn more about the best gluten-free bread.

Bread is a staple of many people’s diets worldwide. While most types of bread do not contain dietary cholesterol, some may include animal products high in saturated fats. Foods that are high in saturated fats are usually high in dietary cholesterol.

However, studies have shown that dietary cholesterol has little effect on blood cholesterol levels. Saturated fat is more likely to increase LDL cholesterol levels in our blood, along with refined carbohydrates such as white bread.

People should try to increase their fiber intake, including eating more whole grain bread types, which can help to lower cholesterol levels. This can reduce a person’s risk of stroke and heart attack.

Fairview, Sanford health care systems plan to merge

Updated: 6:15 p.m.

Nearly a decade after unsuccessfully attempting a merger, South Dakota-based Sanford Health and Minnesota’s Fairview Health Services said Tuesday they’re again in talks to combine.

The two regional health care giants say they intend to complete a merger next year. The new entity would be called Sanford Health and be run by Sanford’s current CEO. The deal would include the University of Minnesota hospitals, which Fairview purchased in 1997.

“The synergies between the two organizations are going to allow us to marshal the collective resources of both organizations together to better serve our patients and help us deliver on a promise of world-class care to every single patient,” said Sanford Health President and CEO Bill Gassen in an interview with MPR News.

Financial details and any cost-cutting plans tied to the proposed merger were not immediately disclosed.

In 2013, the two health systems pursued a similar merger, but talks broke down amid an onslaught of public criticism. Some state lawmakers pursued legislation that would’ve blocked Sanford from controlling the University of Minnesota hospitals.

Then-Attorney General Lori Swanson raised concerns about a merger because of the role that tax breaks and donations from Minnesota and Minnesotans played in Fairview’s development.

Before you keep reading, take a moment to donate to MPR News. Your financial support ensures that factual and trusted news and context remain accessible to all.

Current Minnesota Attorney General Keith Ellison said late Tuesday his office is investigating the proposed transaction.

If approved this time around, the deal would create a massive health care system stretching across the rural and urban Upper Midwest.

Sioux Falls-based Sanford operates in six states, including Minnesota, and describes itself as the nation’s largest rural health care system, including 47 medical centers and about 45,000 employees.

“Because they’re contiguous, it allows us to be able to coordinate care back and forth,” said Fairview CEO James Hereford. “But frankly, any issues about anti-competitiveness, there’s just no basis for that.”

Sanford Health is named for St. Paul native and University of Minnesota graduate T. Denny Sanford, a philanthropist who made his fortune in the subprime, high-interest credit card business. The Sioux Valley Hospital and Health System was renamed Sanford Health in 2007 after Sanford donated $400 million to the Sioux Falls-based care system.

Minneapolis-based Fairview has 11 hospitals, including the University of Minnesota Medical Center, and about 31,000 employees.

Fairview has been struggling financially for several years. It reported an operating loss in 2021 of $132.6 million on top of a $209 million loss in 2020. In financial statements, the system has pointed to the COVID-19 crisis as contributing to its financial woes, driving up operating costs while driving down the number of nonelective procedures.

Ownership and control of the U’s medical center — the state’s top teaching hospital — is likely to be an issue closely examined by Minnesota lawmakers as it was in 2013. The center would no longer be Minnesota owned.

The University of Minnesota is still weighing the merger possibilities and has questions about the commitment to medical training and research, said Myron Frans, the U’s senior vice president for finance and operations and a former Minnesota budget commissioner.

“We’ve been talking to them, but we have many, many really hard and reasonable questions to ask about how would this merger affect the University of Minnesota,” he told MPR News. “Anything beyond that is still … a source of conjecture on our part.”

The Minnesota Nurses Association late Tuesday said its members will “strongly oppose” the proposed merger because it would “put corporate expansion ahead of patient care.”

MPR News reporters Matt Sepic and Tim Nelson contributed to this report.

Royal Emerald Pharmaceuticals Partners with BioHarvest Sciences to Supply Disruptive Cannabis Solutions to Companies Conducting FDA-Approved Medical Research

This collaboration ensures first-of-their-kind consistent cannabinoid compositions for 575 DEA-licensed cannabis medical research institutions developing cures for PTSD, pain management, anxiety conditions and more

Vancouver, British Columbia and Rehovot, Israel–(Newsfile Corp. – November 16, 2022) – BioHarvest Sciences (CSE: BHSC) (OTCQB: CNVCF) (FSE: 8MV), a leading biotech company focused on plant bio-cells growth for the nutraceutical and the medicinal cannabis markets, today announced the signing of a binding Letter of Intent (LOI) with Royal Emerald Pharmaceuticals (REP), one of only seven Drug Enforcement Administration (DEA) bulk manufacturing registration holders permitted to grow marijuana in the United States for drug related studies approved by the US Food and Drug Administration. This follows BioHarvest’s October 25^th announcement that it could produce unique compositions based on a CBD hemp plant that dramatically increase cannabinoid concentrations (by weight) versus the original plant.

The 3-year initial term (with extension provisions) exclusive arrangement allows the supply of BioHarvest cannabis products for research purposes to pharmaceutical companies, research institutions and other DEA registered entities in the United States federally, and opens the door to advance cannabis research initiatives for drug development through cannabinoid compositions not found in nature. Under the multi-year deal, BioHarvest will be REP’s exclusive provider of cannabis that is produced from non-traditional cultivation methods for scientific, medical and research purposes across the DEA-regulated U.S. market. As part of the LOI, REP has participated with $1 million in BioHarvest’s convertible loan investment instrument that closed its second tranche on November 15^th.

Cannabis-based medicines could be a boon to pharmaceutical companies that are threatened today by the legalization of cannabis. A number of studies have demonstrated a reduction in prescription drug use in Medicaid and Medicare populations directly resulting from the legalization of cannabis. Together, REP and BHSC can offer pharmaceutical companies consistent medical-grade cannabis at highly attractive manufacturing costs with signature patentable compositions tailored for addressing specific medical indications.

“I have unprecedented confidence in BioHarvest’s platform technology and their unique cannabis compositions especially after visiting their R&D and manufacturing facilities in Israel,” said Douglas Rosenberg, Chief Executive Officer of Royal Emerald Pharmaceuticals. “Cannabis-derived drugs are at the precipice of a tremendous opportunity right now as traditional pharmaceutical markets transition in search of innovation and technological advancements that are utilizing cannabis to deliver better solutions. Together we are well-positioned for the expected significant increase in U.S. demand for medical-grade cannabis for therapeutic research. I look forward to a productive and mutually prosperous partnership.”

“We’re extremely proud to partner with Royal Emerald to pair our breakthrough technology with their mission to revolutionize the cannabis medical research ecosystem by introducing unique and patentable cannabis compositions that are non-addictive and effectively treat a myriad of issues currently ailing our global communities,” said BioHarvest CEO Ilan Sobel. ” BioHarvest and REP are committed to developing life-changing solutions for major medical conditions which today are not being adequately treated by existing, chemically synthesized drugs. Imagine what can be accomplished if researchers and the medical community at large are assured of batch-to-batch consistency and the ability to fine-tune the Cannabis based therapy to specific medical indications. That is truly revolutionary.”

Using a patented technology in which vital plant cells are grown in bioreactors, BioHarvest has the unique ability to produce medicinal grade cannabis with consistent compositions by increasing, controlling, and fine-tuning the concentrations of different major and minor cannabinoids. This could help researchers to potentially develop previously unattainable cures for major health challenges such as ADHD, pain management, sleep disorders, and anxiety.

Dr. Christopher D’Adamo, Director of the University of Maryland School of Medicine’s Center for Integrated Medicine, described BioHarvest’s technology as a major advancement.

“Today marks a historical milestone in the pioneering and development of future full-spectrum cannabis drugs which the medical establishment has been eyeing its potential to address many chronic health indications in need of better treatment options,” D’Adamo said. “In addition, BioHarvest’s ability to provide signature cannabis compositions with a breadth of cannabinoids, and with batch consistency and patentability, will no doubt be a major incentive for companies to actively engage and invest in Cannabis based drugs”.

REP is one of only seven companies in the U.S. that hold DEA bulk-manufacturing licenses for scientific medical research. It is permitted to provide cannabis to at least 575 institutions that have DEA research licenses for cannabis research. They range from pharmaceutical companies to academic and medical institutions to government agencies such as the Department for Veterans Affairs and the National Institute on Drug Abuse. REP also has a General Services Administration license which enables the company together with BioHarvest to apply for major government grants from government agencies for cannabis research.

Under the LOI, and subject to the obtainment of the Israeli health authorities manufacturing license, the cannabis products supplied by BioHarvest will be produced in the facility in Israel. The future establishment of a manufacturing facility at REP’s premises in California is contemplated under certain conditions. The LOI also includes provisions with respect to future potential development of medical drugs by BioHarvest, REP and jointly.

Investor Webinar – Wednesday November 16, 2pm EST | 11am PST

Given the magnitude of this announcement, and what it means for the pioneering of cannabis drug development to focus on major indications that today are not being adequately addressed by pharmaceutical drug companies, the Company will host a special investor event today at 11am PST | 2pm EST, where BioHarvest Sciences CEO Ilan Sobel will be joined by the CEO of Royal Emerald Pharmaceuticals, Douglas Rosenberg. All interested media and investors are invited to preregister via this link: https://us02web.zoom.us/webinar/register/WN_y44ONRvVQ9Ou5bhWtHrvAA

About BioHarvest Sciences Inc.

BioHarvest Sciences Inc. (CSE: BHSC) is a fast-growing biotech firm that has developed a patented bio-cell growth platform technology capable of growing the active and beneficial ingredients in fruit and plants, at an industrial scale, without the need to grow the plant itself. This technology is economical, ensures consistency, and avoids the negative environmental impacts associated with traditional agriculture. BioHarvest is currently focused on nutraceuticals and the medicinal cannabis markets. Visit: www.bioharvest.com.

About Royal Emerald Pharmaceuticals

Royal Emerald Pharmaceuticals is a California-based United States DEA and FDA-registered manufacturer and supplier of non-addictive cannabis products being developed for medical, scientific and research purposes. The company was founded on a shared mission to help veterans, first responders and others service personnel on the front lines that sacrifice for the greater good and as a result suffer from trauma-related issues such as PTSD and other health consequences. Royal Emerald is dedicated to serving our heroes by developing best-in-class cannabis derived pharmaceuticals to address their specific health and medical needs. Visit: https://www.royalemeraldrx.com/.

Contact:

BioHarvest Sciences Inc.
Ilan Sobel, Chief Executive Officer

For further information, please contact:
Dave Ryan, VP Investor Relations & Director Phone: 1 (604) 622-1186
Email: info@bioharvest.com

Royal Emerald Pharmaceuticals
Douglas Rosenberg, Chief Executive Officer

For further information, please contact:
Jackie Devereaux, Director of Communications & Media Relations
Phone 1 (760) 671-6944
Email: jdevereaux@royalemeraldrx.com

Forward Looking Statements

Information set forth in this news release includes forward-looking statements that are based on management’s current estimates, beliefs, intentions, and expectations, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Projected sales of Cannabis products will require the Company to obtain production and/or export licensing which cannot be assured. There is no assurance that the Company’s products will help researchers working on medications for heath challenges such as ADHD, sleep disorders. pain management and anxiety. Marketing products with such claims would require FDA approval in the US and similar approvals in other jurisdictions which would require a lengthy and expensive approval process including clinical trials the outcome of which would be uncertain and cannot be assured. Although the Company believes that the consistency and customizability of its products will make them more suitable for medical and scientific research there is no assurance that the customers of Royal Emerald or other medical/scientific users of cannabis products will choose the Company’s products over traditionally grown Cannabis Products. Adoption of new and disruptive products can be subject to structural obstacles and the uncertainty of market acceptance which may delay or even prevent adoption. There is no assurance that the Company and /or Royal Emerald will develop medical drugs which normally involves lengthy and expensive research and approval processes which may be beyond the ability of these parties and significant uncertainty of success.

All forward-looking statements are inherently uncertain and actual results may be affected by a number of material factors beyond our control. Readers should not place undue reliance on forward-looking statements. BHSC does not intend to update forward-looking statement disclosures other than through our regular management discussion and analysis disclosures.

Neither the Canadian Securities Exchange nor its Regulation Services Provider accept responsibility for the adequacy or accuracy of this release.

Royal Emerald Pharmaceuticals Partners with BioHarvest Sciences to Supply Disruptive Cannabis Solutions to Companies Conducting FDA-Approved Medical Research

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/144473

Michelle Obama says she had to ease nation into a first lady with Black hair: ‘Let me keep my hair straight. Let’s get health care passed’

Michelle Obama says she intentionally waited until she left the White House to finally wear her hair in braids, suggesting that the country was “just getting adjusted” to a Black woman as first lady.

“They ain’t ready for it!” Obama told Ellen DeGeneres on Tuesday, as she kicked off a nationwide book tour in Washington to promote her new self-help book and memoir “The Light We Carry.”

“The code of ethics at a workplace, as Black women we deal with it, the whole thing about do you show up with your natural hair?” Obama said.

“Braids, ya’ll!” Obama exclaimed to applause from the sold-out crowd, as she motioned to her hairstyle.

“We gotta ease up on the people,” Obama quipped about how she wore her hair while living in the executive mansion.

“They tripped out when Barack wore a tan suit,” Obama continued, referring to the then-president’s 2014 sartorial choice that quickly became a viral sensation.

“The great indignity, the scandal of the Obama administration,” the former first lady said with a laugh.

Dramatizing what she imagined the reaction would’ve been if she debuted braids while in the White House, Obama took on the tone of her critics and said, “Remember when she wore braids? Those are terrorist braids! Those are revolutionary braids!”

“Let me keep my hair straight,” Obama continued. “Let’s get health care passed.”

Obama said she’d sometimes tease her team by mentioning a desire to switch up her look.

“I would get my staff all worried, too. I was like, ‘I was thinking about getting braids,’” Obama chuckled as she stroked her hair.

“That’s the African American experience,” Obama said, “but women in offices that are worried, ‘Should I wear skirts? Should I wear pantyhose?’ I hate pantyhose.”

“But when you’re carrying all this other stuff, this mask, these differences and you’re trying to do your job, it’s just an extra burden on overcoming,” she told DeGeneres.

Obama’s appearance at the Warner Theatre coincided with former President Trump’s announcement on Tuesday in Florida that he was launching a 2024 White House bid. No mention was made of Trump by name at the event, but Obama did reflect on the “painful” experience of his 2016 victory.

“You don’t want to make this personal, but as I write in the book, it hurt. It hurt because you wonder was it a rebuke of the eight years, the sacrifice we made? Was it complacency? What was it?” Obama, 58, said.

“We sacrificed a lot to make that set of changes and because not enough people voted, that was that.”

In the early days of the COVID-19 pandemic, Obama said, “You’re looking at the world and you’re looking at the world literally fall apart before your very eyes. And for us, it was particularly painful because we knew this would happen.”

“I mean, if you — if you guys recall, I said, ‘Don’t vote for this guy.”

“I have to say, and I should have listened to you, I regret voting for him,” DeGeneres, an outspoken Trump critic, deadpanned. “I thought he was a good guy,” DeGeneres joked.

Saying while she didn’t want to “talk too much politics,” Obama told the audience, “The truth is, we have a vested interest in making sure that more people feel seen.”

“That more people feel like they have a stake in what’s going on. People need jobs, they need housing, they need to feel like they can get ahead, they need to feel like they have a stake in this world and then they won’t tear it apart,” she said.

“They won’t tear it apart with racism, or with violence, or with crime because it’s theirs.”

—Updated at 10:50 a.m.